Dysregulated post-transcriptional control of COX-2 gene expression in cancer

被引:69
作者
Dixon, DA
机构
[1] Vanderbilt Univ, Dept Surg, Med Ctr, Surg Oncol Res Lab, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Dept Canc Biol, Med Ctr, Nashville, TN 37232 USA
关键词
COX-2; cyclooxygenase; prostaglandins; cancer; post-transcriptional regulation; mRNA stability; AU-rich; element; RNA-binding protein;
D O I
10.2174/1381612043453171
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The cyclooxygenase-2 (COX-2) enzyme catalyzes the rate-limiting step of prostaglandin formation in pathogenic states. The molecular regulation of COX-2 gene expression is normally tightly regulated on transcriptional and post-transcriptional levels. However, loss of function at either level of COX-2 gene regulation promotes constitutive COX-2 overexpression which plays a key role in carcinogenesis, particularly colorectal tumorigenesis. Current work investigating the regulatory mechanisms of COX-2 expression has demonstrated post-transcriptional regulation to play a central role. Rapid COX-2 mRNA decay and translational inhibition is mediated through a conserved AU-rich element (ARE) present within the 3'-untranslated region (3'UTR). The COX-2 ARE exerts its control through association with ARE RNA-binding proteins. These trans-acting regulatory factors influence the fate of COX-2 mRNA by controlling mRNA degradation, stabilization, or translation. Recent evidence demonstrates the functional significance rapid mRNA decay and translational inhibition play in controlling COX-2 gene expression and that, if dysregulated, allow for overexpression of COX-2 and other associated angiogenic factors detected in neoplasia.
引用
收藏
页码:635 / 646
页数:12
相关论文
共 164 条
[1]   Ras signaling pathway proteins as therapeutic targets [J].
Adjei, AA .
CURRENT PHARMACEUTICAL DESIGN, 2001, 7 (16) :1581-1594
[2]  
AGHIB DF, 1990, ONCOGENE, V5, P707
[3]   Novel role for RNA-binding protein CUGBP2 in mammalian RNA editing - CUGBP2 modulates C to U editing of apolipoprotein B mRNA by interacting with apobec-1 and ACF, the apobec-1 complementation factor [J].
Anant, S ;
Henderson, JO ;
Mukhopadhyay, D ;
Navaratnam, N ;
Kennedy, S ;
Min, J ;
Davidson, NO .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (50) :47338-47351
[4]   Arsenic trioxide in multiple myeloma: Rationale and future directions [J].
Anderson, KC ;
Boise, LH ;
Louie, R ;
Waxman, S .
CANCER JOURNAL, 2002, 8 (01) :12-25
[5]   STRUCTURE OF THE HUMAN CYCLO-OXYGENASE-2 GENE [J].
APPLEBY, SB ;
RISTIMAKI, A ;
NEILSON, K ;
NARKO, K ;
HLA, T .
BIOCHEMICAL JOURNAL, 1994, 302 :723-727
[6]  
Araki Y, 2003, CANCER RES, V63, P728
[7]   TGF-BETA EXPRESSION IN THE HUMAN COLON - DIFFERENTIAL IMMUNOSTAINING ALONG CRYPT EPITHELIUM [J].
AVERY, A ;
PARASKEVA, C ;
HALL, P ;
FLANDERS, KC ;
SPORN, M ;
MOORGHEN, M .
BRITISH JOURNAL OF CANCER, 1993, 68 (01) :137-139
[8]   RNA-binding protein TIAR is essential for primordial germ cell development [J].
Beck, ARP ;
Miller, IJ ;
Anderson, P ;
Streuli, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (05) :2331-2336
[9]   Tristetraprolin and other CCCH tandem zinc-finger proteins in the regulation of mRNA turnover [J].
Blackshear, PJ .
BIOCHEMICAL SOCIETY TRANSACTIONS, 2002, 30 :945-952
[10]  
Blaxall BC, 2000, MOL CARCINOGEN, V28, P76